OncoSpear ApS: Financial statements 2022
CVR: 42093734
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
OncoSpear ApS (CVR 42093734) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -639,949 and a net result of DKK -1,090,059 compared with DKK -26,170 the year before. Equity in the 2022 report amounted to DKK 7,112,160. The solvency ratio was 94.7%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -639,949
- Profit/Loss
- DKK -1,090,059
- Equity
- DKK 7,112,160
- Total Assets
- DKK 7,509,608
- Employees
- 1
Official annual report
Keep an eye on OncoSpear ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of September 30, 2022, Alexander Bharmal Demoulin has joined the board of directors of OncoSpear ApS.
As of September 30, 2022, Debora Catharina Dumont has joined the board of directors of OncoSpear ApS.
OncoSpear ApS has published its annual report for 2021. Gross profit came to DKK -25,963, and the net result was DKK -26,170.
About OncoSpear ApS
OncoSpear ApS is a Danish company of the type Anpartsselskab based in Hinnerup, founded in 2021. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Geert Gilbert Tackaert and Niels Jonas Heilskov Graversen. The company is owned by SPICA THERAPEUTICS. The company has 8 employees (2026). In 2025, the company reported a gross profit of DKK 2,927,421 and a net result of DKK -821,765 compared with DKK -6,461,139 the year before. Equity in the 2025 report amounted to DKK 569,861.